Nordic Bioscience has introduced nordicEndotrophin, a fully automated, high-precision assay designed to selectively quantify the intact 77-amino-acid Endotrophin hormone.
The assay, qualified in the CAP/CLIA-certified Nordic Bioscience lab, offers prognostic utility in fibrosis and cancer studies, enhancing the company’s existing product line.
NordicEndotrophin complements nordicPRO-C6 and nordicPRO-C3, in-house versions of the FDA-supported PRO-C6 and CE-approved PRO-C3 assays.
Together, these assays provide a comprehensive solution for assessing the fibro-inflammatory axis in chronic diseases such as cardiovascular, metabolic, and renal disorders.
The recent deployment of PRO-C3 on Roche IVD platforms highlights the new Endotrophin assay’s role in strengthening risk stratification and pharmacodynamic monitoring.
Endotrophin, first identified in 2012, is a collagen-derived hormone released from type VI collagen, which contributes to fibroblast activation and fibrosis across organs.
The inflammation account for around 40% of deaths in Western countries. Obesity further exacerbates these conditions by activating fibroblasts in the liver, kidney, and heart.
Patients with a two-fold increase in circulating Endotrophin levels face a 100% increased risk of mortality.
Quantifying Endotrophin aids researchers in linking wound healing and fibrotic progression to patient outcomes, supporting precision medicine approaches.
While PRO-C6 measures the formation of the total pool of type VI collagen, nordicEndotrophin specifically targets the intact 77-amino-acid hormone.
The specificity provides additional risk stratification and prognostic value, complementing PRO-C6’s insights into fibrosis-driven pharmacodynamics.
Nordic Bioscience CEO Morten Karsdal said: “Endotrophin is a significant prognostic biomarker to emerge. Evidenced in a study of HFpEF patients, Endotrophin and PRO-C6 outperformed NT-proBNP in HFpEF for mortality and hospitalisation risk.
“Together with PRO-C3, quantifying this fibro-inflammatory hormone will refine patient stratification and treatment monitoring across obesity, fibrotic diseases, and autoimmune endotypes.”
NordicEndotrophin is available in Nordic Bioscience’s CAP/CLIA-certified laboratory in Herlev, Denmark, on fully automated, high-accuracy, high-throughput platforms.
Clients are encouraged to co-measure nordicPRO-C3 and nordicPRO-C6 with nordicEndotrophin to accelerate drug fibro-inflammatory profiling.
The assays facilitate precise risk stratification, dose selection, patient enrichment, proof-of-mechanism, and treatment monitoring in anti-fibrotic and oncology trials.
